Literature DB >> 26324366

Genetic Cancer Susceptibility Testing: Increased Technology, Increased Complexity.

Peter Paul Yu1, Julie M Vose2, Daniel F Hayes3.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26324366     DOI: 10.1200/JCO.2015.63.3628

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.

Authors:  Julia R Trosman; Christine B Weldon; Michael P Douglas; Allison W Kurian; R Kate Kelley; Patricia A Deverka; Kathryn A Phillips
Journal:  J Natl Compr Canc Netw       Date:  2017-02-10       Impact factor: 11.908

2.  Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

Authors:  Xiaotong Qiu; Yong Wang; Fen Liu; Lihong Peng; Chen Fang; Xiaoyin Qian; Xinwei Zhang; Qian Wang; Zhehao Xiao; Renfang Chen; Shangkun Yuan; Yong Li
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

3.  Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.

Authors:  Allison W Kurian; Yun Li; Ann S Hamilton; Kevin C Ward; Sarah T Hawley; Monica Morrow; M Chandler McLeod; Reshma Jagsi; Steven J Katz
Journal:  J Clin Oncol       Date:  2017-04-12       Impact factor: 50.717

Review 4.  Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib.

Authors:  Rohit K Jain; Hongbin Chen
Journal:  Lung Cancer (Auckl)       Date:  2017-10-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.